Suppr超能文献

临床代谢特征可提高结直肠癌肝转移患者手术治疗中组织学生长模式的预后价值。

Clinico-metabolic characterization improves the prognostic value of histological growth patterns in patients undergoing surgery for colorectal liver metastases.

机构信息

Department of Surgical Oncology, Jules Bordet Institute, Free University of Brussels (ULB), Brussels, Belgium.

Department of Nuclear Medicine, Jules Bordet Institute, Free University of Brussels (ULB), Brussels, Belgium.

出版信息

J Surg Oncol. 2021 May;123(8):1773-1783. doi: 10.1002/jso.26466. Epub 2021 Mar 22.

Abstract

BACKGROUND AND OBJECTIVES

The histological growth pattern (HGP) represents a strong prognostic factor in patients undergoing surgery for colorectal liver metastases (CRLM). We evaluated whether the combination of HGP with clinico-metabolic parameters could improve its prognostic value.

METHODS

In a series of 108 patients undergoing resection of CRLM, the HGP of CRLM was scored according to international guidelines. Baseline clinico-metabolic clinical status was evaluated using a metabolic-Clinical Risk Score (mCRS), combining traditional Memorial Sloan Kettering-CRS parameters with the tumor-to-liver glucose uptake ratio as measured with Fluorodeoxyglucose/positron emission tomography.

RESULTS

In patients with desmoplastic HGP (DHGP) CRLM (20% of all patients), 5- and 10-years overall survival (OS) and disease free survival (DFS) were 66% and 43% and 37% and 24.5%, as compared with 35% and 21% and 11% and 11% in the non-DHGP group (p = 0.07 and 0.054). Among DHGP patients, those with a low-risk mCRS had improved postoperative outcomes, 5- and 10-years OS and DFS reaching 83.3% and 62.5% and 50% and 33%, as compared with 18% and 0% and 0% and 0% in high-risk mCRS patients (p = 0.007 and 0.003). In contrast, mCRS did not influence postoperative survivals in non-DHGP patients.

CONCLUSIONS

Combining the clinico-metabolic characteristics with the HGP may improve prognostication in patients undergoing surgery for CRLM.

摘要

背景与目的

组织学生长模式(HGP)是结直肠癌肝转移(CRLM)患者接受手术治疗的一个强有力的预后因素。我们评估了 HGP 与临床代谢参数的结合是否可以提高其预后价值。

方法

在 108 例接受 CRLM 切除术的患者中,根据国际指南对 CRLM 的 HGP 进行评分。使用代谢-临床风险评分(mCRS)评估基线临床代谢临床状态,该评分结合了传统 Memorial Sloan Kettering-CRS 参数和氟脱氧葡萄糖/正电子发射断层扫描测量的肿瘤与肝脏葡萄糖摄取率。

结果

在具有纤维组织增生型 HGP(DHGP)的 CRLM 患者(所有患者的 20%)中,5 年和 10 年总生存率(OS)和无病生存率(DFS)分别为 66%和 43%和 37%和 24.5%,而非 DHGP 组分别为 35%和 21%和 11%和 11%(p=0.07 和 0.054)。在 DHGP 患者中,mCRS 低风险的患者术后结局得到改善,5 年和 10 年 OS 和 DFS 分别达到 83.3%和 62.5%和 50%和 33%,而 mCRS 高风险的患者则分别为 18%和 0%和 0%和 0%(p=0.007 和 0.003)。相比之下,mCRS 并未影响非 DHGP 患者的术后生存。

结论

将临床代谢特征与 HGP 相结合可以改善接受 CRLM 手术治疗的患者的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1739/8251827/c9088bff5cad/JSO-123-1773-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验